BiotechTube
Epiome

Epiome

London, United Kingdom· Est.
epiome.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Epiome is an early-stage, privately-held biotech leveraging artificial intelligence to decode epigenetic information for diagnostic applications. While currently in stealth mode with limited public disclosure, its core mission is to build a proprietary platform that identifies epigenetic biomarkers, which could lead to earlier and more precise disease detection. The company is headquartered in London, UK, and appears to be in a pre-revenue, foundational technology development phase. Its success will hinge on validating its AI platform, securing partnerships, and translating computational discoveries into viable diagnostic products.

Diagnostics

Technology Platform

AI-driven platform for the analysis of epigenetic data (e.g., DNA methylation, histone modifications) to discover and validate novel biomarkers for diagnostic applications.

Opportunities

The convergence of AI and epigenetics offers a significant opportunity to unlock complex biological data for earlier and more precise disease diagnosis.
The growing demand for non-invasive liquid biopsies and personalized medicine creates a large addressable market for novel epigenetic biomarkers.
The platform could also service pharmaceutical companies in need of biomarkers for drug development and patient stratification.

Risk Factors

High technical risk that epigenetic signatures may not be sufficiently robust for reliable diagnostics.
Intense competition from other AI-biomarker discovery firms and large tech companies entering the health space.
Significant regulatory and commercialization challenges in translating a computational discovery into an approved, clinically-validated diagnostic test.

Competitive Landscape

Epiome operates in a competitive space that includes pure-play AI biomarker discovery companies (e.g., Freenome, Grail in early detection), large genomics firms (e.g., Illumina's spinouts), and tech giants (e.g., Google, NVIDIA) with healthcare AI divisions. Differentiation will require demonstrating superior performance in epigenetic-specific analysis and forming strategic partnerships to access data and clinical channels.

More companies in United Kingdom →